Novelos Therapeutics Inc (NVLT.PK)

NVLT.PK

About

Operates as a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of Cancer and Hepatitis. The Company's drugs are based on oxidized glutathione, a natural metabolite that is part of the glutathione pathway. This pathway is the primary determinant of intracellular redox (oxidation/red... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.62
Market Cap (Mil.):	$24.97
Shares Outstanding (Mil.):	57.40
Dividend:	--
Yield (%):	--

Financials

	NVLT.PK	Industry	Sector
P/E (TTM):	--	30.37	30.65
EPS (TTM):	-0.23	--	--
ROI:	-124.83	19.50	18.83
ROE:	-142.17	20.27	19.74

Latest News about NVLT.PK

» More NVLT.PK News

Competitors

	Price	Change
Johnson & Johnson (JNJ.N)	$85.15	-1.21
Bayer AG (BAYGn.DE)	€84.19	+0.37
Bayer AG (BAYE.F)	--	--
Sanofi SA (SASY.PA)	€80.79	-0.76
Roche Holding Ltd. (ROG.VX)	CHF230.40	+1.50
Bristol Myers Squibb Co. (BMY.N)	$46.36	-0.49
Bristol Myers Squibb Co. (BMYMP.PK)	--	--
Pfizer Inc. (PFE.N)	$29.23	-0.17
Spectrum Pharmaceuticals, Inc. (SPPI.OQ)	$8.23	-0.05
GlaxoSmithKline plc (GSK.L)	1,665.00p	-11.00

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Novelos Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Novelos Therapeutics, Inc. (NVLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
ValuEngine Detailed Valuation Report for NVLT Provider: ValuEngine, Inc.	$127.00 Buy
Novelos Therapeutics, Inc. (NVLT) - Financial and Strategic SWOT Analysis Review Provider: GlobalData	$125.00 Buy
Novelos Therapeutics, Inc. (NVLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.